The HIV Drug That Came Back From the Dead

Trial 051 compared Idvynso against whatever patients were already taking. The results here were even more interesting: just 1% of Idvynso patients lost viral suppression versus 5% who stayed on their old regimen.

As for the CD4 scare? At the lower dose, no meaningful differences in immune cell counts showed up between Idvynso and the comparator groups. The fire extinguisher, it turns out, just needed a smaller nozzle.

Why Two Drugs Instead of Three?

For decades, the standard playbook for HIV treatment has been three drugs in one pill. Think of it like a three-lock security system: even if one lock fails, the other two keep the door shut. But three drugs also mean three sets of potential side effects, three chances for interactions with other medications, and sometimes real consequences for organs like the kidneys.

The trend in HIV care has been moving toward two-drug regimens for patients whose virus is already under control. ViiV Healthcare's Dovato (dolutegravir plus lamivudine) represented a significant shift as a daily oral two-drug pill. ViiV Healthcare's Cabenuva took it further with injectable shots every one to two months.

Idvynso carves out its own lane. It's the first two-drug oral regimen that avoids both integrase inhibitors (INSTIs) and tenofovir, two drug classes that dominate nearly every other HIV combo on the market. For patients who can't tolerate those classes, or whose doctors want to avoid the long-term metabolic effects of tenofovir, Idvynso offers something genuinely new.

One pill. Once a day. Two drugs instead of three. No tenofovir. No integrase inhibitor. That's a meaningful menu expansion for a disease where people take medication every single day for the rest of their lives.

The Gilead-Shaped Elephant in the Room

Let's talk about the competitive reality. Gilead's HIV franchise generated $20.8 billion in sales in 2025, with Biktarvy alone pulling in $14.3 billion. That's not a competitor you dethrone overnight.

Analysts at BMO Capital Markets called Idvynso's approval enough to make Merck a "meaningful competitor" in HIV, but they also expect "limited impacts" on Gilead's dominance in the near term. Gilead isn't standing still either; its twice-yearly injectable Yeztugo is projected to hit $800 million in sales in 2026.

The more interesting angle is what Idvynso means for Merck's portfolio. The company's blockbuster cancer drug Keytruda faces patent expiration in 2028, and Merck desperately needs new revenue streams. Idvynso won't replace Keytruda's billions, but it plants a flag in a therapeutic area with predictable, long-term demand. People with HIV stay on treatment for life, and that kind of recurring revenue is pharmaceutical gold.

GlobalData analysts see potential for Idvynso to become a top seller in Merck's virology portfolio. Ongoing trials could eventually expand the label to treatment-naive patients (those starting therapy for the first time), which would significantly widen the addressable market.

The Bigger Picture

Idvynso will be available in U.S. pharmacies after May 11, 2026. It's already approved in Japan.

The approval comes with the usual fine print: it's not for people with active hepatitis B, those taking certain enzyme-inducing drugs, or patients with a history of treatment failure. Warnings include the risk of severe skin reactions like Stevens-Johnson syndrome.

But the real story here isn't just another HIV drug approval. It's a reminder that drug development isn't always a straight line. Islatravir looked dead in the water four years ago. Merck's bet that a lower dose could rescue the molecule paid off in a way that genuinely expands options for people living with HIV.

In pharma, second acts are rare. This one delivered.

One Failed Trial Just Gutted Indivior's Entire R&D Operation

Indivior's experimental opioid addiction drug flopped in Phase 2, and now the company is gutting its research team. Wall Street didn't flinch, but the long-term implications of becoming a one-drug company are harder to ignore.